Facilitated By

San Antonio Medical Foundation

Phase III Randomized, Double-Blind, Placebo-Controlled Multicenter Study In Adults To Determine The Safety, Efficacy, And Immunogenicity Of AZD1222, A Non-Replicating ChADOxi Vector Vaccine, For The Prevention Of COVID-19

Brooke Army Medical Center

Brooke Army Medical Center (BAMC) at Fort Sam Houston, Texas, is proud to provide safe, quality care to our military service members, their families, veterans and civilian emergency patients as the most robust and productive healthcare organization within the Military Health System (MHS).

Principal Investigator(s)
Email for information
Funded by
Geneva
Research Start Date
Status
Active

The aim of the present study is to assess the safety, efficacy, and immunogenicity of AZD1222 for the prevention of COVID-19.

Collaborative Project
Clinical Care
Infectious Disease
The appearance of name-brand products in this article does not constitute endorsement by Brooke Army Medical Center, the U.S. Army Medical Center, the U.S. Army Medical Department, the U.S. Army Office of the Surgeon General, the Department of the Army, the Department of Defense, or the U.S. Government of the information, products, or services contained therein.